BMS-690514
- Generic Name
- BMS-690514
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N6O2
- CAS Number
- 859853-30-8
- Unique Ingredient Identifier
- VKU5X213Q7
- Background
BMS-690514 has been investigated for the treatment of Breast Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT01167244
- Locations
- ๐ฏ๐ต
Local Institution, Koto-Ku, Tokyo, Japan
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT01068704
- Locations
- ๐บ๐ธ
Texas Oncology-Abilene, Abilene, Texas, United States
๐บ๐ธTexas Oncology-Beaumont, Beaumont, Texas, United States
๐บ๐ธUs Oncology Central Pharmacy, Fort Worth, Texas, United States
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00743938
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธHema/Oncology Assoc. Of Nepa, Dunmore, Pennsylvania, United States
๐บ๐ธCancer Center Of The Carolinas, Greenville, South Carolina, United States
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT00516451
- Locations
- ๐ฏ๐ต
Local Institution, Chuo-Ku, Tokyo, Japan
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT00420186
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธPenn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
๐ฌ๐งLocal Institution, Manchester, Greater Manchester, United Kingdom
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 89
- Registration Number
- NCT00329004
- Locations
- ๐ช๐ธ
Local Institution, Barcelona, Spain
๐บ๐ธIndiana University Med Center, Indianapolis, Indiana, United States
๐บ๐ธThe University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.